psigryph
Kitchener, CA · 1 known investors
Psigryph develops Nanopect, a patented plant-derived nanodelivery system that transports bioactive molecules (nutrients, cannabinoids, pharmaceuticals) across cell membranes of plants, animals, and humans to increase bioavailability. The technology, derived from Montmorency sour cherries, targets industries including food and beverage, agriculture, pharmaceutical, and cannabis.
Founders & leadership
ST
Sean ThompsoninCo-Founder, CEO and Board MemberSean Thompson held corporate development and clinical research roles at major pharmaceutical companies including GSK and Roche, where he led licensing and acquisition transactions, and later served as VP of Corporate Development at YM BioSciences (acquired by Gilead). He holds a B.Sc. from the University of Waterloo and is founder of Psigryph, which develops a plant-derived nanodelivery system for bioactive molecules.
Investors · 1
Frequently asked questions
- What does psigryph do?
- Psigryph develops Nanopect, a patented plant-derived nanodelivery system that transports bioactive molecules (nutrients, cannabinoids, pharmaceuticals) across cell membranes of plants, animals, and humans to increase bioavailability. The technology, derived from Montmorency sour cherries, targets industries including food and beverage, agriculture, pharmaceutical, and cannabis.
- Who founded psigryph?
- psigryph was founded by Sean Thompson.
- Who are psigryph's investors?
- psigryph's investors include Foresight.
- Where is psigryph headquartered?
- psigryph is headquartered in Kitchener, CA.